trial

Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

NCTId NCT03929497
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 96 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2020-09-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
96 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-04-22
Primary completion
2020-09-01
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Lu AF11167

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

30 total
Burgas, BulgariaKazanlak, BulgariaNovi Iskar, BulgariaPleven, BulgariaSevlievo, BulgariaSofia, BulgariaVarna, BulgariaVarna, BulgariaVarna, BulgariaVratsa, BulgariaTallinn, EstoniaTartu, Estonia

Linked catalysts

1
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophr — primary completion2020-09-01

Facts & assertions

4 sourced
Enrollment
96
Phase
PHASE2
Primary Completion Date
2020-09-01
Status
TERMINATED
relationships
The graph out of here
drug
Lu AF11167
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication